EP3403676A1 - Degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use and preparation method therefor - Google Patents
Degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use and preparation method therefor Download PDFInfo
- Publication number
- EP3403676A1 EP3403676A1 EP16906621.4A EP16906621A EP3403676A1 EP 3403676 A1 EP3403676 A1 EP 3403676A1 EP 16906621 A EP16906621 A EP 16906621A EP 3403676 A1 EP3403676 A1 EP 3403676A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- magnesium alloy
- high strength
- resistant high
- ductility
- biomedical use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910000861 Mg alloy Inorganic materials 0.000 title claims abstract description 229
- 230000007797 corrosion Effects 0.000 title claims abstract description 114
- 238000005260 corrosion Methods 0.000 title claims abstract description 114
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000011777 magnesium Substances 0.000 claims abstract description 41
- 238000009749 continuous casting Methods 0.000 claims abstract description 28
- 239000006104 solid solution Substances 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 238000001125 extrusion Methods 0.000 claims abstract description 10
- 239000000155 melt Substances 0.000 claims description 77
- 239000007789 gas Substances 0.000 claims description 69
- 229910045601 alloy Inorganic materials 0.000 claims description 58
- 239000000956 alloy Substances 0.000 claims description 58
- 238000002844 melting Methods 0.000 claims description 42
- 230000008018 melting Effects 0.000 claims description 42
- 238000003756 stirring Methods 0.000 claims description 33
- 229910052749 magnesium Inorganic materials 0.000 claims description 23
- 238000001816 cooling Methods 0.000 claims description 22
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 21
- 239000002994 raw material Substances 0.000 claims description 21
- 238000005266 casting Methods 0.000 claims description 20
- 229910052726 zirconium Inorganic materials 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 229910052779 Neodymium Inorganic materials 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 238000005520 cutting process Methods 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 230000002792 vascular Effects 0.000 abstract description 13
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 description 23
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- 210000004204 blood vessel Anatomy 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 11
- 239000002184 metal Substances 0.000 description 11
- 229910052802 copper Inorganic materials 0.000 description 10
- 239000010949 copper Substances 0.000 description 10
- 238000005204 segregation Methods 0.000 description 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 9
- 229910052786 argon Inorganic materials 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 238000009413 insulation Methods 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 238000002513 implantation Methods 0.000 description 7
- 229910052761 rare earth metal Inorganic materials 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229910052727 yttrium Inorganic materials 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- 229910009378 Zn Ca Inorganic materials 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910052688 Gadolinium Inorganic materials 0.000 description 3
- 238000005275 alloying Methods 0.000 description 3
- 229920006237 degradable polymer Polymers 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 238000003723 Smelting Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000013079 quasicrystal Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000037408 Device failure Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000788 chromium alloy Substances 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C23/00—Alloys based on magnesium
Definitions
- the present invention relates to a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use and the preparation method therefor, which pertains to the field of medical material preparation techniques.
- the vascular stents used clinically are mainly made of inert metal materials such as stainless steel, nickel-titanium alloys and cobalt-chromium alloys.
- the implantation of such stents in the human body can provide long-lasting mechanical support for the blood vessels at the lesion, avoid the elastic retraction of the blood vessels, and lower the restenosis rate of the blood vessels.
- a stent made of inert metal materials as a foreign body causes excessive hyperplasia of the intima of the blood vessels after implantation, which not only causes vascular restenosis and late thrombosis, but also requires long-term antiplatelet therapy.
- degradable vascular stents There are two types of degradable vascular stents that have obtained registration certificates or entered clinical trials: one as degradable polymer stents, and the other as degradable magnesium alloy stents.
- Degradable polymer stents has problems of low mechanical properties, difficulty in processing, and in vivo degradation products that can easily cause inflammation and swelling. A large amount of clinical data shows that patients have a chance of up to 16% of developing advanced restenosis after implantation of a polymer stent.
- degradable magnesium alloy stents mainly have the following advantages: (1) it can be completely degraded after being implanted into the human body. A magnesium alloy stent can be completely absorbed by the body generally within 4 months after implantation.
- the feature of complete degradability of magnesium alloy stents not only can improve the compliance and naturalness of the blood vessel to a certain extent, but can also re-introduce a stent at the same lesion site in a blood vessel without causing stent overlapping, which is especially suitable for the treatment of cardiovascular diseases in infants and young children.
- magnesium is an essential element for the human body to maintain normal physiological functions while the blood vessel stent has a minute size (a hollow tubular shape with a diameter of approximately 2 mm, a wall thickness of approximately 0.1 to 0.2 mm, and a length of approximately 15 mm) and release a small amount of metal ions in the degradation process
- the small amount of magnesium ions released during the degradation of the magnesium alloy stent not only does not cause harm to the human body, but would rather supplement magnesium to the body, so as to meet the need in magnesium for normal physiological functions of the body.
- the magnesium alloy stent can be completely absorbed by the body, non-invasive examination can be performed during follow-ups after stent implantation.
- Appropriate support strength Magnesium alloy as a vascular stent material does not have the problem of insufficient strength that polymer materials have, allowing the vascular stent to have an appropriate support strength.
- magnesium alloys leading to poor corrosion resistance, and corrosion is particularly severe in a corrosive environment in which chloride ions (Cl - ) are present or when the medium has a pH ⁇ 11.5.
- chloride ions Cl -
- the in vivo environment has a pH of around 7.4, with a large amount of chloride ions present in the body fluids, which, in addition to the complicated corrosive nature of the in vivo environment, may lead to change in the corrosion rate of magnesium alloys in the body.
- medical corrosion-resistant magnesium alloys have been developed, such as the medical corrosion-resistant magnesium alloy disclosed in CN101062427A and the medical high strength and toughness corrosion-resistant magnesium alloy disclosed in CN101288776A .
- magnesium pertains to a metal of a densely packed hexagonal crystalline structure, with few independent slip systems at room temperature except the base slip.
- high strength magnesium alloys have been developed, such as the high strength and high plasticity magnesium alloy and the preparation method thereof disclosed in CN101643872A , and the high plasticity magnesium alloy and the preparation method thereof disclosed in CN101985714A .
- the magnesium alloys in the above patent documents contain Al element and heavy rare earth elements (Y, Gd, etc.). It is well-known that the Al element may cause some degenerative neurological diseases such as dialysis encephalopathy syndrome, senile dementia, and is considered to be a harmful neurotoxic element to the human body. Although Y, Gd and other heavy rare earth elements can increase the strength and corrosion resistance of magnesium alloys, their biological effects are not yet clear and it is generally believed that the accumulation of heavy rare earth elements in the body manifest a toxic action.
- CN101629260A discloses a medical absorbable Mg-Zn-Mn-Ca magnesium alloy.
- the components and weight percentages in the magnesium alloy are: 1.0 to 5.0% of Zn, 0.2 to 2.0% of Mn, 0.1 to 3.0% of Ca, and the balance of Mg.
- the magnesium alloy has fair biocompatibility and mechanical properties and can be made into implantable devices such as bone nails and bone plates.
- the magnesium alloy cannot be used for the preparation of vascular stents, primarily for the reasons including: (1) compromised corrosion-resistant performance of the magnesium alloy due to the addition of the Mn element with a relatively high content, resulting in too fast degradation rate and frequent occurring of local uneven degradation; and (2) poor ductility of the alloy and difficulty in plastic processing, making it difficult to achieve secondary molding.
- CN103184379A discloses a biodegradable Mg-Gd-Zn-Ag-Zr type magnesium alloy and the preparation method thereof.
- the components and weight percentages of the magnesium alloy are: 5 to 10% of Gd, 0.5 to 3% of Zn, 0.1 to 1% of Ag, 0.1 to 1% of Zr, and the balance of Mg.
- the magnesium alloy can be used as an implant material with low degradation rate and uniform corrosion.
- the deficiency of this magnesium alloy lies in the relatively high content of the heavy rare earth element Gd in the components ( ⁇ 5%), whereas the Gd element is considered toxic and disadvantageous in improving the biocompatibility of the alloy.
- the magnesium alloy contains the expensive Ag element and requires strict preservation and smelting conditions, thereby increasing the cost.
- an object of the present invention is to provide a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use and a preparation method thereof.
- the magnesium alloy has the advantages of being non-toxic and fully degradable, good corrosion resistance as well as high strength and toughness and the like, and can be used for preparing a vascular stent.
- the present invention first provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use, wherein the composition of components of the magnesium alloy comprises 1.0 to 4.5% of Nd, 0.2 to 2.0% of Zn, 0 to 1.0% of Ca, 0 to 1.0% of Zr, and balance of Mg, with regard to a total weight of the magnesium alloy of 100%.
- the composition of the components comprises 1.5 to 3.5% of Nd, 0.1 to 1.0% of Zn, 0.1 to 1.0% of Ca, 0.2 to 1.0% of Zr, and balance of Mg, with regard to a total weight of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to the present invention of 100%.
- the composition of components of the magnesium alloy comprises 1.5 to 2.5% of Nd, 0.4 to 0.8% of Zn, 0.4 to 0.6% of Ca, 0.4 to 0.8% of Zr, and balance of Mg, with regard to a total weight of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to the present invention of 100%.
- the contents of components of this preferred magnesium alloy enables better overall mechanical performance and biological corrosion performance to be achieved thereby.
- the total amount of inclusion elements other than Mg, Nd, Zn, Ca, and Zr contained in the magnesium alloy is 0.05% or less.
- the magnesium alloy may be conferred with better overall mechanical performance and biological corrosion performance.
- the above degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use is prepared by at least the step of: preparing a magnesium alloy ingot according to the components and weight percentage in the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use, wherein the raw materials used comprise at least: pure Zn, a Mg-Nd master alloy, and pure magnesium. More preferably, the raw materials used further comprise pure Ca and/or a Mg-Zr master alloy.
- the pure Zn used has a purity of 99.99 wt% or more
- the pure Ca used has a purity of 99.99 wt% or more
- the Mg-Nd master alloy used is a Mg-30wt%Nd master alloy
- the Mg-Zr master alloy used is a Mg-30wt%Zr master alloy
- the pure magnesium used has a purity of 99.99 wt% or more.
- the resultant magnesium alloy ingot may have a size of ⁇ 110 to 150 mm in diameter and 2200 to 2600 mm in length.
- the above preparation of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use further comprises: cutting the resultant magnesium alloy ingot to a certain length, and subjecting it to solid solution treatment before extruding, so as to obtain the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use.
- the temperature of the solid solution treatment is 480 to 540°C
- the duration of the solid solution treatment is 8 to 12 hours
- the extrusion is performed at an extruding ratio of 5 to 30 in an environment at 280 to 420°C
- the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use is obtained after the extrusion as a round rod with a diameter of ⁇ 20 to 40 mm.
- each element in the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use provided by the present invention are as follows, respectively:
- the incorporation of Nd brings about an excellent aging precipitation strengthening and solid solution strengthening effect to the magnesium alloy, because Nd forms a strengthening phase Mg2Nd in the magnesium alloy and this strengthening phase can increase the strength and plasticity of the alloy.
- the incorporation of Nd can greatly increase the electrode potential of the magnesium alloy substrate and reduce the difference in electric potential between the galvanic corrosion of the substrate and the second phase, thereby significantly improving the corrosion resistance of the magnesium alloy.
- Nd belongs to light rare earth elements and has good biological safety.
- Zn is an element that has significant influence on cell growth and development and is a necessary micronutrient element in the human body. Zn can enhance the immunity in the human body and maintain growth and development in the body. In vitro experiments showed that Zn can maintain the barrier function of vascular endothelial cell membranes.
- Zn has a 6.2% solid solubility in the magnesium alloy, and plays a role in the solid solution strengthening of the magnesium alloy, while effectively promoting the occurrence of non-basal surface slipping in the magnesium alloy at room temperature and improving the plastic processibility of the magnesium alloy.
- Zn is another highly effective alloying element other than Al. In addition, when the Zn content is less than 2%, the local corrosion in the magnesium alloy tends to be reduced, effectively improving the corrosion resistance of the magnesium alloy.
- Ca can refine the grains in the magnesium alloy, which is effective in strengthening the fine grains, and significantly improve the moldability and strength of the magnesium alloy. Ca can also suppress the oxidation of the molten metal during the smelting of the magnesium alloy and reduce internal defects in ingots. Ca can reduce the microbattery effect in a magnesium alloy and increase the corrosion resistance of the magnesium alloy. Meanwhile, Ca is also one of the most abundant elements in the human body, and about 99% of Ca is present in bone marrows and teeth in vivo, with the remaining primarily distributed in body fluids for participating in certain important enzyme reactions. Ca plays an important role in maintaining the normal contraction of the heart, neuromuscular excitability, coagulation, and normal secretion of endocrine hormones, as well as in maintenance of cell membrane integrity, and the like.
- Zr has a strong solid solution strengthening effect and can significantly increase the strength of a magnesium alloy.
- Zr is also the most effective grain refining agent to date and has a strong grain refinement effect.
- Zr can significantly improve the tensile strength of the magnesium alloy at room temperature, improve corrosion resistance and reduce stress corrosion susceptibility.
- the addition of Zr into a Zn-containing magnesium alloy can reduce the tendency of embrittlement and temper embrittlement in the magnesium alloy, and can also reduce the contents of Fe, Al, Si, and other impurities in the alloy. Extensive domestic and overseas studies show that addition of Zr in a small amount into a magnesium alloy is not cytotoxic.
- the present invention also provides a preparation method for the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use described above, which comprises at least the step of: preparing a magnesium alloy ingot by means of vacuum semi-continuous casting and according to the components and weight percentage in the above-mentioned magnesium alloy, wherein the raw materials used comprise at least: pure Zn, a Mg-Nd master alloy and pure magnesium.
- the raw materials used further comprise pure Ca and/or a Mg-Zr master alloy.
- the pure Zn used has a purity of 99.99 wt% or more
- the pure Ca used has a purity of 99.99 wt% or more
- the Mg-Nd master alloy used is a Mg-30wt%Nd master alloy
- the Mg-Zr master alloy used is a Mg-30wt%Zr master alloy
- the pure magnesium used has a purity of 99.99 wt% or more.
- the vacuum semi-continuous casting comprises the following steps:
- the resultant magnesium alloy ingot has a size of ⁇ 110 to 150 mm in diameter and 2200 to 2600 mm in length, and more preferably ⁇ 120 ⁇ 2400 mm.
- the above preparation method further comprises the following steps: cutting the obtained magnesium alloy ingot to a certain length, and subjecting it to solid solution treatment before extruding, so as to obtain the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use.
- the temperature of the solid solution treatment is 480 to 540°C (more preferably 520°C)
- the duration of the solid solution treatment is 8 to 12 hours (more preferably 10 hours)
- the extrusion is performed at an extruding ratio of 5 to 30 (more preferably 25) in an environment at 280 to 420°C (more preferably 330°C)
- the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use is obtained after the extrusion as a round rod with a diameter of ⁇ 20 to 40 mm (more preferably ⁇ 25mm).
- the present invention Compared with the existing magnesium alloys for degradable vascular stents, the present invention has the following advantages:
- This example provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use.
- the composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Nd, 0.4% of Zn, 0.4% of Ca, 0.4% of Zr, and balance of Mg.
- the magnesium alloy was prepared by the following steps:
- the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use had a tensile strength of 246 MPa, a yield strength of 207 MPa and an elongation of 34%, as well as good plasticity and mechanical properties.
- the corrosion rate of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use in artificial plasma was 0.26 mm/year, in a uniform corrosion manner. Biological test results showed that the material had no obvious cytotoxicity and good blood compatibility, which met the requirements for intravascular stent materials.
- This example provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use.
- the composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 2.0% of Nd, 0.6% of Zn, 0.5% of Ca, 0.6% of Zr, and balance of Mg.
- the magnesium alloy was prepared by the following steps:
- the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use had a tensile strength of 277 MPa, a yield strength of 224 MPa and an elongation of 28%, as well as good plasticity and mechanical properties.
- the corrosion rate of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use in artificial plasma was 0.24 mm/year, in a uniform corrosion manner. Biological test results showed that the material had no obvious cytotoxicity and good blood compatibility, which met the requirements for intravascular stent materials.
- This example provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use.
- the composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 2.5% of Nd, 0.8% of Zn, 0.6% of Ca, 0.8% of Zr, and balance of Mg.
- the magnesium alloy was prepared by the following steps:
- the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use had a tensile strength of 289 MPa, a yield strength of 232 MPa and an elongation of 25%, as well as good plasticity and mechanical properties.
- the corrosion rate of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use in artificial plasma was 0.22 mm/year, in a uniform corrosion manner. Biological test results showed that the material had no obvious cytotoxicity and good blood compatibility, which met the requirements for intravascular stent materials.
- This example provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use.
- the composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Nd, 0.4% of Zn, 0.4% of Zr, and balance of Mg.
- the magnesium alloy was prepared by the following steps:
- the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use had a tensile strength of 223 MPa, a yield strength of 188 MPa and an elongation of 24%.
- the corrosion rate of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use in artificial plasma was 0.32 mm/year.
- Biological test results showed that the material had no obvious cytotoxicity and good blood compatibility, which met the requirements for the biocompatibility of intravascular stent materials.
- This example provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use.
- the composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Nd, 0.4% of Zn, 0.4% of Ca, and balance of Mg.
- the magnesium alloy was prepared by the following steps:
- the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use had a tensile strength of 228 MPa, a yield strength of 196 MPa and an elongation of 21%.
- the corrosion rate of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use in artificial plasma was 0.36 mm/year.
- Biological test results showed that the material had no obvious cytotoxicity and good blood compatibility, which met the requirements for the biocompatibility of intravascular stent materials.
- This example provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use.
- the composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Nd, 2.0% of Zn, 0.4% of Ca, 0.4% of Zr, and balance of Mg.
- the magnesium alloy was prepared by the following steps:
- the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use had a tensile strength of 256 MPa, a yield strength of 219 MPa and an elongation of 18%.
- the corrosion rate of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use in artificial plasma was 0.44 mm/year.
- Biological test results showed that the material had no obvious cytotoxicity and good blood compatibility, which met the requirements for the biocompatibility of intravascular stent materials.
- This comparative example provides a biomedical magnesium alloy.
- the composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Y, 0.4% of Zn, 0.4% of Zr, and balance of Mg.
- the magnesium alloy was prepared by the following steps:
- the biomedical magnesium alloy had a tensile strength of 216 MPa, a yield strength of 176 MPa and an elongation of 19%.
- the corrosion rate of the biomedical magnesium alloy in artificial plasma was 0.37 mm/year.
- This comparative example provides a biomedical magnesium alloy.
- the composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Y, 0.4% of Zn, 0.4% of Ca, and balance of Mg.
- the magnesium alloy was prepared by the following steps:
- the biomedical magnesium alloy had a tensile strength of 213 MPa, a yield strength of 172 MPa and an elongation of 22%.
- the corrosion rate of the biomedical magnesium alloy in artificial plasma was 0.43 mm/year.
- This comparative example provides a biomedical magnesium alloy.
- the composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Y, 2.0% of Zn, 0.4% of Ca, and balance of Mg.
- the magnesium alloy was prepared by the following steps:
- the biomedical magnesium alloy had a tensile strength of 236 MPa, a yield strength of 204 MPa and an elongation of 17%.
- the corrosion rate of the biomedical magnesium alloy in artificial plasma was 0.48 mm/year. Table 1. Magnesium alloy composition and related properties Example No.
- the magnesium alloy prepared by implementing the most preferred embodiments of the present invention has a tensile strength of 246 to 289 MPa, a yield strength of 207 to 232 MPa and an elongation rate of up to 25 to 34%, which meets the requirements for the mechanical properties of intravascular stent materials. Its corrosion rate in artificial plasma can reach 0.22 to 0.26 mm/year, which meets the requirement for the corrosion resistance of intravascular stent materials.
- the magnesium alloy has no obvious cytotoxicity and good blood compatibility, which meets the requirements for the biocompatibility of intravascular stent materials.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
- The present invention relates to a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use and the preparation method therefor, which pertains to the field of medical material preparation techniques.
- At present, the vascular stents used clinically are mainly made of inert metal materials such as stainless steel, nickel-titanium alloys and cobalt-chromium alloys. The implantation of such stents in the human body can provide long-lasting mechanical support for the blood vessels at the lesion, avoid the elastic retraction of the blood vessels, and lower the restenosis rate of the blood vessels. However, a stent made of inert metal materials as a foreign body causes excessive hyperplasia of the intima of the blood vessels after implantation, which not only causes vascular restenosis and late thrombosis, but also requires long-term antiplatelet therapy. In recent years, the use of drug-eluting stents has reduced the restenosis rate of blood vessels to about 5%. However, upon completion of the drug release, the stent body permanently remains in the body. There is a great difference in mechanical properties between the stent as a foreign body and vascular tissues, which can cause chronic damage to the blood vessel and, at a later stage, atrophy of the middle vascular layers and intimal hyperplasia, and eventually lead to restenosis of the blood vessels. For pediatric patients, the implantation of a fixed-size stent will hinder the gradual enlargement of the blood vessel, and it is even more difficult to adapt to the needs of their growth and development. In view of the above reasons, the development of biodegradable vascular stents has become a hot research project in various countries.
- There are two types of degradable vascular stents that have obtained registration certificates or entered clinical trials: one as degradable polymer stents, and the other as degradable magnesium alloy stents. Degradable polymer stents has problems of low mechanical properties, difficulty in processing, and in vivo degradation products that can easily cause inflammation and swelling. A large amount of clinical data shows that patients have a chance of up to 16% of developing advanced restenosis after implantation of a polymer stent. As compared to degradable polymer stents, degradable magnesium alloy stents mainly have the following advantages: (1) it can be completely degraded after being implanted into the human body. A magnesium alloy stent can be completely absorbed by the body generally within 4 months after implantation. The feature of complete degradability of magnesium alloy stents not only can improve the compliance and naturalness of the blood vessel to a certain extent, but can also re-introduce a stent at the same lesion site in a blood vessel without causing stent overlapping, which is especially suitable for the treatment of cardiovascular diseases in infants and young children. (2) Good biocompatibility. Since magnesium is an essential element for the human body to maintain normal physiological functions while the blood vessel stent has a minute size (a hollow tubular shape with a diameter of approximately 2 mm, a wall thickness of approximately 0.1 to 0.2 mm, and a length of approximately 15 mm) and release a small amount of metal ions in the degradation process, the small amount of magnesium ions released during the degradation of the magnesium alloy stent not only does not cause harm to the human body, but would rather supplement magnesium to the body, so as to meet the need in magnesium for normal physiological functions of the body. (3) Because the magnesium alloy stent can be completely absorbed by the body, non-invasive examination can be performed during follow-ups after stent implantation. (4) Appropriate support strength. Magnesium alloy as a vascular stent material does not have the problem of insufficient strength that polymer materials have, allowing the vascular stent to have an appropriate support strength.
- However, the low standard electrode potential of magnesium alloys (-2.36V SCE) leads to poor corrosion resistance, and corrosion is particularly severe in a corrosive environment in which chloride ions (Cl-) are present or when the medium has a pH ≤11.5. As bio-implantation materials, magnesium alloys must strictly meet the necessary mechanical and morphological requirements during service, and therefore should not have a too fast rate of degradation by corrosion. The in vivo environment has a pH of around 7.4, with a large amount of chloride ions present in the body fluids, which, in addition to the complicated corrosive nature of the in vivo environment, may lead to change in the corrosion rate of magnesium alloys in the body. For these reasons, medical corrosion-resistant magnesium alloys have been developed, such as the medical corrosion-resistant magnesium alloy disclosed in
CN101062427A and the medical high strength and toughness corrosion-resistant magnesium alloy disclosed inCN101288776A . - Another factor that limits the widespread use of magnesium alloys lies in its low plasticity at room temperature and the difficulty in deformation processing. This is because magnesium pertains to a metal of a densely packed hexagonal crystalline structure, with few independent slip systems at room temperature except the base slip. In view of the issue of poor plasticity at room temperature of magnesium alloys, high strength magnesium alloys have been developed, such as the high strength and high plasticity magnesium alloy and the preparation method thereof disclosed in
CN101643872A , and the high plasticity magnesium alloy and the preparation method thereof disclosed inCN101985714A . - Most of the magnesium alloys in the above patent documents contain Al element and heavy rare earth elements (Y, Gd, etc.). It is well-known that the Al element may cause some degenerative neurological diseases such as dialysis encephalopathy syndrome, senile dementia, and is considered to be a harmful neurotoxic element to the human body. Although Y, Gd and other heavy rare earth elements can increase the strength and corrosion resistance of magnesium alloys, their biological effects are not yet clear and it is generally believed that the accumulation of heavy rare earth elements in the body manifest a toxic action.
-
CN101629260A discloses a medical absorbable Mg-Zn-Mn-Ca magnesium alloy. The components and weight percentages in the magnesium alloy are: 1.0 to 5.0% of Zn, 0.2 to 2.0% of Mn, 0.1 to 3.0% of Ca, and the balance of Mg. The magnesium alloy has fair biocompatibility and mechanical properties and can be made into implantable devices such as bone nails and bone plates. However, the magnesium alloy cannot be used for the preparation of vascular stents, primarily for the reasons including: (1) compromised corrosion-resistant performance of the magnesium alloy due to the addition of the Mn element with a relatively high content, resulting in too fast degradation rate and frequent occurring of local uneven degradation; and (2) poor ductility of the alloy and difficulty in plastic processing, making it difficult to achieve secondary molding. -
CN103184379A discloses a biodegradable Mg-Gd-Zn-Ag-Zr type magnesium alloy and the preparation method thereof. The components and weight percentages of the magnesium alloy are: 5 to 10% of Gd, 0.5 to 3% of Zn, 0.1 to 1% of Ag, 0.1 to 1% of Zr, and the balance of Mg. The magnesium alloy can be used as an implant material with low degradation rate and uniform corrosion. However, the deficiency of this magnesium alloy lies in the relatively high content of the heavy rare earth element Gd in the components (≥5%), whereas the Gd element is considered toxic and disadvantageous in improving the biocompatibility of the alloy. In addition, the magnesium alloy contains the expensive Ag element and requires strict preservation and smelting conditions, thereby increasing the cost. - In summary, it is urgent to develop a novel biomedical magnesium alloy that is non-toxic, fully degradable, has good corrosion resistance, high strength and ductility, and explores the possibility of its application in intravascular stents.
- To solve the above technical problems, an object of the present invention is to provide a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use and a preparation method thereof. The magnesium alloy has the advantages of being non-toxic and fully degradable, good corrosion resistance as well as high strength and toughness and the like, and can be used for preparing a vascular stent.
- In order to achieve the above object, the present invention first provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use, wherein the composition of components of the magnesium alloy comprises 1.0 to 4.5% of Nd, 0.2 to 2.0% of Zn, 0 to 1.0% of Ca, 0 to 1.0% of Zr, and balance of Mg, with regard to a total weight of the magnesium alloy of 100%.
- According to a preferred embodiment of the present invention, the composition of the components comprises 1.5 to 3.5% of Nd, 0.1 to 1.0% of Zn, 0.1 to 1.0% of Ca, 0.2 to 1.0% of Zr, and balance of Mg, with regard to a total weight of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to the present invention of 100%.
- According to a more preferred embodiment of the present invention, the composition of components of the magnesium alloy comprises 1.5 to 2.5% of Nd, 0.4 to 0.8% of Zn, 0.4 to 0.6% of Ca, 0.4 to 0.8% of Zr, and balance of Mg, with regard to a total weight of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to the present invention of 100%. The contents of components of this preferred magnesium alloy enables better overall mechanical performance and biological corrosion performance to be achieved thereby.
- In the above degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use, preferably, with regard to a total weight of the magnesium alloy of 100%, the total amount of inclusion elements other than Mg, Nd, Zn, Ca, and Zr contained in the magnesium alloy is 0.05% or less. In the present invention, by strictly controlling the contents of Fe, Cu, Ni and other impurities, the magnesium alloy may be conferred with better overall mechanical performance and biological corrosion performance.
- According to a specific embodiment of the present invention, preferably, the above degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use is prepared by at least the step of: preparing a magnesium alloy ingot according to the components and weight percentage in the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use, wherein the raw materials used comprise at least: pure Zn, a Mg-Nd master alloy, and pure magnesium. More preferably, the raw materials used further comprise pure Ca and/or a Mg-Zr master alloy. Further preferably, the pure Zn used has a purity of 99.99 wt% or more, the pure Ca used has a purity of 99.99 wt% or more, the Mg-Nd master alloy used is a Mg-30wt%Nd master alloy, the Mg-Zr master alloy used is a Mg-30wt%Zr master alloy, and the pure magnesium used has a purity of 99.99 wt% or more. In addition, the resultant magnesium alloy ingot may have a size of Φ110 to 150 mm in diameter and 2200 to 2600 mm in length.
- According to a specific embodiment of the present invention, preferably, the above preparation of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use further comprises: cutting the resultant magnesium alloy ingot to a certain length, and subjecting it to solid solution treatment before extruding, so as to obtain the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use. Here, more preferably, the temperature of the solid solution treatment is 480 to 540°C, the duration of the solid solution treatment is 8 to 12 hours, the extrusion is performed at an extruding ratio of 5 to 30 in an environment at 280 to 420°C, and the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use is obtained after the extrusion as a round rod with a diameter of Φ20 to 40 mm.
- The roles of each element in the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use provided by the present invention are as follows, respectively:
The incorporation of Nd brings about an excellent aging precipitation strengthening and solid solution strengthening effect to the magnesium alloy, because Nd forms a strengthening phase Mg2Nd in the magnesium alloy and this strengthening phase can increase the strength and plasticity of the alloy. Also, the incorporation of Nd can greatly increase the electrode potential of the magnesium alloy substrate and reduce the difference in electric potential between the galvanic corrosion of the substrate and the second phase, thereby significantly improving the corrosion resistance of the magnesium alloy. In addition, Nd belongs to light rare earth elements and has good biological safety. - Zn is an element that has significant influence on cell growth and development and is a necessary micronutrient element in the human body. Zn can enhance the immunity in the human body and maintain growth and development in the body. In vitro experiments showed that Zn can maintain the barrier function of vascular endothelial cell membranes. In view of the mechanical properties of magnesium alloys, Zn has a 6.2% solid solubility in the magnesium alloy, and plays a role in the solid solution strengthening of the magnesium alloy, while effectively promoting the occurrence of non-basal surface slipping in the magnesium alloy at room temperature and improving the plastic processibility of the magnesium alloy. Zn is another highly effective alloying element other than Al. In addition, when the Zn content is less than 2%, the local corrosion in the magnesium alloy tends to be reduced, effectively improving the corrosion resistance of the magnesium alloy.
- The inclusion of Ca can refine the grains in the magnesium alloy, which is effective in strengthening the fine grains, and significantly improve the moldability and strength of the magnesium alloy. Ca can also suppress the oxidation of the molten metal during the smelting of the magnesium alloy and reduce internal defects in ingots. Ca can reduce the microbattery effect in a magnesium alloy and increase the corrosion resistance of the magnesium alloy. Meanwhile, Ca is also one of the most abundant elements in the human body, and about 99% of Ca is present in bone marrows and teeth in vivo, with the remaining primarily distributed in body fluids for participating in certain important enzyme reactions. Ca plays an important role in maintaining the normal contraction of the heart, neuromuscular excitability, coagulation, and normal secretion of endocrine hormones, as well as in maintenance of cell membrane integrity, and the like.
- Zr has a strong solid solution strengthening effect and can significantly increase the strength of a magnesium alloy. Zr is also the most effective grain refining agent to date and has a strong grain refinement effect. In addition, Zr can significantly improve the tensile strength of the magnesium alloy at room temperature, improve corrosion resistance and reduce stress corrosion susceptibility. The addition of Zr into a Zn-containing magnesium alloy can reduce the tendency of embrittlement and temper embrittlement in the magnesium alloy, and can also reduce the contents of Fe, Al, Si, and other impurities in the alloy. Extensive domestic and overseas studies show that addition of Zr in a small amount into a magnesium alloy is not cytotoxic.
- On the other hand, the present invention also provides a preparation method for the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use described above, which comprises at least the step of: preparing a magnesium alloy ingot by means of vacuum semi-continuous casting and according to the components and weight percentage in the above-mentioned magnesium alloy, wherein the raw materials used comprise at least: pure Zn, a Mg-Nd master alloy and pure magnesium. Preferably, the raw materials used further comprise pure Ca and/or a Mg-Zr master alloy.
- In the above preparation method, preferably, the pure Zn used has a purity of 99.99 wt% or more, the pure Ca used has a purity of 99.99 wt% or more, the Mg-Nd master alloy used is a Mg-30wt%Nd master alloy, the Mg-Zr master alloy used is a Mg-30wt%Zr master alloy, and the pure magnesium used has a purity of 99.99 wt% or more.
- In the above preparation method, preferably, the vacuum semi-continuous casting comprises the following steps:
- (1) the raw materials are melted in a vacuum melting furnace with a melt temperature controlled at 740 to 760°C during melting, and after the raw materials are completely melted, an inert gas is introduced for stirring by gas in a vacuum environment with a stirring time of 30 to 45 min;
- (2) after the stirring is completed, a mixed gas of SF6 and CO2 is introduced to the surface of the melt for protection while the temperature of the melt is raised to 760 to 780°C and kept for 30 to 40 min, and then the temperature of the melt is lowered to 700 to 720°C and the melt is allowed to stand for 90 to 120 min;
- (3) casting is then carried out on a semi-continuous casting machine; during the semi-continuous casting process, a gas mixture of SF6 and CO2 is used for protection, the temperature of the melt in the vacuum melting furnace is controlled at 700 to 720°C, with the temperature of the melt in a crystallizer at 680 to 690°C and a speed of ingot-drawing of 30 to 50 mm/min, and high pressure water-cooling is applied at 300 to 500 mm close to the crystallizer while air-cooling is applied at a lower region, thereby obtaining the magnesium alloy ingot.
- In the above preparation method, preferably, the resultant magnesium alloy ingot has a size of Φ110 to 150 mm in diameter and 2200 to 2600 mm in length, and more preferably Φ120 × 2400 mm.
- According to a specific embodiment of the present invention, preferably, the above preparation method further comprises the following steps: cutting the obtained magnesium alloy ingot to a certain length, and subjecting it to solid solution treatment before extruding, so as to obtain the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use. Here, more preferably, the temperature of the solid solution treatment is 480 to 540°C (more preferably 520°C), the duration of the solid solution treatment is 8 to 12 hours (more preferably 10 hours), the extrusion is performed at an extruding ratio of 5 to 30 (more preferably 25) in an environment at 280 to 420°C (more preferably 330°C), and the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use is obtained after the extrusion as a round rod with a diameter of Φ20 to 40 mm (more preferably Φ25mm).
- Compared with the existing magnesium alloys for degradable vascular stents, the present invention has the following advantages:
- 1. The magnesium alloy of the present invention has an ideal corrosion resistance in vivo, and is uniformly eroded and degraded, so as to avoid premature failure of implant materials due to excessive local corrosion, thereby achieving an ideal supporting effect of a biodegradable material.
- 2. The present invention avoids the neurotoxicity caused by the Al element in Al-containing magnesium alloys in the composition design, and does not contain heavy rare earth elements (Y, Gd, etc.), while the selected alloying and microalloying elements are all non-cytotoxic within the proposed composition range and have good biocompatibility.
- 3. Under the same conditions in the preparation process, as compared to the existing magnesium alloys for degradable vascular stents, in the magnesium alloy of the present invention, the contents of alloying elements, especially rare earth elements, are lower than those in the WE43 alloy, which not only greatly improves the blood compatibility of the alloy, but also leads to less segregation of elements in the alloy, better corrosion resistance, remarkably reduced corrosion rate, and relatively uniform corrosion.
- 4. The quasi-crystalline phase occurring in the magnesium alloy prepared by the method of the present invention has excellent corrosion resistance, which greatly improves the corrosion resistance of the alloy. While the occurrence of the quasi-crystal phase significantly improves the corrosion resistance of magnesium alloys, the rigidity of the magnesium alloy can also be improved to some extent due to the special properties of quasicrystals, which solves the problem of insufficient rigidity of the magnesium alloy as a degradable blood vessel stent.
- 5. The magnesium alloy of the present invention has excellent comprehensive mechanical properties, excellent corrosion resistance and good biocompatibility after being processed by extrusion. The magnesium alloy prepared by the present invention has a tensile strength of 246 to 289 MPa, a yield strength of 207 to 232 MPa and an elongation rate of 25 to 34%, which meets the requirements for the mechanical properties of intravascular stent materials. Its corrosion rate in artificial plasma can reach 0.22 to 0.26mm/year, which meets the requirement for the corrosion resistance of intravascular stent materials. In addition, the magnesium alloy has no obvious cytotoxicity and good blood compatibility, which meets the requirements for the biocompatibility of intravascular stent materials.
- For clearer understanding of the technical features, objects, and advantages of the present invention, the technical solutions of the present invention will be described in detail below, but it should not be construed as limiting to the scope of the present invention.
- This example provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use. The composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Nd, 0.4% of Zn, 0.4% of Ca, 0.4% of Zr, and balance of Mg.
- The magnesium alloy was prepared by the following steps:
- (1) In a vacuum melting furnace, pure magnesium having a purity of 99.99 wt% or more, pure Zn having a purity of 99.99 wt% or more, pure Ca having a purity of 99.99 wt% or more, a Mg-30wt%Nd master alloy and a Mg-30wt%Zr master alloy were successively melted, and the melt temperature during melting was controlled at 740 to 760°C. After the raw materials were completely melted, argon gas was introduced to conduct gas stirring in a vacuum environment with a stirring time of 40 min.
- (2) After the stirring was completed, a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) was introduced to the surface of the melt for protection, and at the same time, the temperature of the melt was raised to 760 to 780°C and kept for 30 min. After the high temperature insulation, the melting furnace was powered off, and the temperature of the melt was controlled at 700 to 720°C and the melt was allowed to stand for 90 min.
- (3) Subsequently, a copper crystallizer was used for the ingot casting on a semi-continuous casting machine. The magnesium alloy melt was introduced into a diverter plate placed in the core of the inner sleeve of the crystallizer, and was diverted by the diverter plate into the space formed by the metal inner sleeve and the dummy bar of the crystallizer. At the same time, the protective gas ring was opened to provide a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) to the alloy melt for protection. During the semi-continuous casting process, the temperature of the melt in the vacuum melting furnace was controlled at 700 to 720°C, the temperature of the melt in the crystallizer was 680 to 690°C, and the speed of ingot-drawing was 40 mm/min. High pressure water-cooling was applied at 400 mm close to the crystallizer, and air-cooling was applied at a lower region.
- (4) The Mg-Nd-Zn-Ca-Zr magnesium alloy semi-continuous ingot obtained from the casting had a size of Φ120×2400mm. The ingot had an appearance free of cracks and shrinkage, with a smooth and clean surface, fine and uniform structures, and no solute segregation.
- (5) The resultant Mg-Nd-Zn-Ca-Zr magnesium alloy ingot was cut to a certain length, subjected to solid solution treatment at 520°C for 10 hours, and then extruded at 330°C to form a round rod having a diameter of Φ25 mm, and thus the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use was obtained.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use had a tensile strength of 246 MPa, a yield strength of 207 MPa and an elongation of 34%, as well as good plasticity and mechanical properties. The corrosion rate of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use in artificial plasma was 0.26 mm/year, in a uniform corrosion manner. Biological test results showed that the material had no obvious cytotoxicity and good blood compatibility, which met the requirements for intravascular stent materials.
- This example provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use. The composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 2.0% of Nd, 0.6% of Zn, 0.5% of Ca, 0.6% of Zr, and balance of Mg.
- The magnesium alloy was prepared by the following steps:
- (1) In a vacuum melting furnace, pure magnesium having a purity of 99.99 wt% or more, pure Zn having a purity of 99.99 wt% or more, pure Ca having a purity of 99.99 wt% or more, a Mg-30wt%Nd master alloy and a Mg-30wt%Zr master alloy were successively melted, and the melt temperature during melting was controlled at 740 to 760°C. After the raw materials were completely melted, argon gas was introduced to conduct gas stirring in a vacuum environment with a stirring time of 40 min.
- (2) After the stirring was completed, a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) was introduced to the surface of the melt for protection, and at the same time, the temperature of the melt was raised to 760 to 780°C and kept for 30 min. After the high temperature insulation, the melting furnace was powered off, and the temperature of the melt was controlled at 700 to 720°C and the melt was allowed to stand for 90 min.
- (3) Subsequently, a copper crystallizer was used for the ingot casting on a semi-continuous casting machine. The magnesium alloy melt was introduced into a diverter plate placed in the core of the inner sleeve of the crystallizer, and was diverted by the diverter plate into the space formed by the metal inner sleeve and the dummy bar of the crystallizer. At the same time, the protective gas ring was opened to provide a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) to the alloy melt for protection. During the semi-continuous casting process, the temperature of the melt in the vacuum melting furnace was controlled at 700 to 720°C, the temperature of the melt in the crystallizer was 680 to 690°C, and the speed of ingot-drawing was 40 mm/min. High pressure water-cooling was applied at 400 mm close to the crystallizer, and air-cooling was applied at a lower region.
- (4) The Mg-Nd-Zn-Ca-Zr magnesium alloy semi-continuous ingot obtained from the casting had a size of Φ120×2400mm. The ingot had an appearance free of cracks and shrinkage, with a smooth and clean surface, fine and uniform structures, and no solute segregation.
- (5) The resultant Mg-Nd-Zn-Ca-Zr magnesium alloy ingot was cut to a certain length, subjected to solid solution treatment at 520°C for 10 hours, and then extruded at 330°C to form a round rod having a diameter of Φ25 mm, and thus the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use was obtained.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use had a tensile strength of 277 MPa, a yield strength of 224 MPa and an elongation of 28%, as well as good plasticity and mechanical properties. The corrosion rate of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use in artificial plasma was 0.24 mm/year, in a uniform corrosion manner. Biological test results showed that the material had no obvious cytotoxicity and good blood compatibility, which met the requirements for intravascular stent materials.
- This example provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use. The composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 2.5% of Nd, 0.8% of Zn, 0.6% of Ca, 0.8% of Zr, and balance of Mg.
- The magnesium alloy was prepared by the following steps:
- (1) In a vacuum melting furnace, pure magnesium having a purity of 99.99 wt% or more, pure Zn having a purity of 99.99 wt% or more, pure Ca having a purity of 99.99 wt% or more, a Mg-30wt%Nd master alloy and a Mg-30wt%Zr master alloy were successively melted, and the melt temperature during melting was controlled at 740 to 760°C. After the raw materials were completely melted, argon gas was introduced to conduct gas stirring in a vacuum environment with a stirring time of 40 min.
- (2) After the stirring was completed, a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) was introduced to the surface of the melt for protection, and at the same time, the temperature of the melt was raised to 760 to 780°C and kept for 30 to 40 min. After the high temperature insulation, the melting furnace was powered off, and the temperature of the melt was controlled at 700 to 720°C and the melt was allowed to stand for 90 min.
- (3) Subsequently, a copper crystallizer was used for the ingot casting on a semi-continuous casting machine. The magnesium alloy melt was introduced into a diverter plate placed in the core of the inner sleeve of the crystallizer, and was diverted by the diverter plate into the space formed by the metal inner sleeve and the dummy bar of the crystallizer. At the same time, the protective gas ring was opened to provide a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) to the alloy melt for protection. During the semi-continuous casting process, the temperature of the melt in the vacuum melting furnace was controlled to 700 to 720°C, the temperature of the melt in the crystallizer was 680 to 690°C, and the speed of ingot-drawing was 40 mm/min. High pressure water-cooling was applied at 400 mm close to the crystallizer, and air-cooling was applied at a lower region.
- (4) The Mg-Nd-Zn-Ca-Zr magnesium alloy semi-continuous ingot obtained from the casting had a size of Φ120×2400mm. The ingot had an appearance free of cracks and shrinkage, with a smooth and clean surface, fine and uniform structures, and no solute segregation.
- (5) The resultant Mg-Nd-Zn-Ca-Zr magnesium alloy ingot was cut to a certain length, subjected to solid solution treatment at 520°C for 10 hours, and then extruded at 330°C to form a round rod having a diameter of Φ25 mm, and thus the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use was obtained.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use had a tensile strength of 289 MPa, a yield strength of 232 MPa and an elongation of 25%, as well as good plasticity and mechanical properties. The corrosion rate of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use in artificial plasma was 0.22 mm/year, in a uniform corrosion manner. Biological test results showed that the material had no obvious cytotoxicity and good blood compatibility, which met the requirements for intravascular stent materials.
- This example provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use. The composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Nd, 0.4% of Zn, 0.4% of Zr, and balance of Mg.
- The magnesium alloy was prepared by the following steps:
- (1) In a vacuum melting furnace, pure magnesium having a purity of 99.99 wt% or more, pure Zn having a purity of 99.99 wt% or more, a Mg-30wt%Nd master alloy and a Mg-30wt%Zr master alloy were successively melted, and the melt temperature during melting was controlled at 740 to 760°C. After the raw materials were completely melted, argon gas was introduced to conduct gas stirring in a vacuum environment with a stirring time of 40 min.
- (2) After the stirring was completed, a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) was introduced to the surface of the melt for protection, and at the same time, the temperature of the melt was raised to 760 to 780°C and kept for 30 min. After the high temperature insulation, the melting furnace was powered off, and the temperature of the melt was controlled at 700 to 720°C and the melt was allowed to stand for 90 min.
- (3) Subsequently, a copper crystallizer was used for the ingot casting on a semi-continuous casting machine. The magnesium alloy melt was introduced into a diverter plate placed in the core of the inner sleeve of the crystallizer, and was diverted by the diverter plate into the space formed by the metal inner sleeve and the dummy bar of the crystallizer. At the same time, the protective gas ring was opened to provide a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) to the alloy melt for protection. During the semi-continuous casting process, the temperature of the melt in the vacuum melting furnace was controlled at 700 to 720°C, the temperature of the melt in the crystallizer was 680 to 690°C, and the speed of ingot-drawing was 40 mm/min. High pressure water-cooling was applied at 400 mm close to the crystallizer, and air-cooling was applied at a lower region.
- (4) The Mg-Nd-Zn-Zr magnesium alloy semi-continuous ingot obtained from the casting had a size of Φ120×2400mm. The ingot had an appearance free of cracks and shrinkage, with a smooth and clean surface, fine and uniform structures, and no solute segregation.
- (5) The resultant Mg-Nd-Zn-Zr magnesium alloy ingot was cut to a certain length, subjected to solid solution treatment at 520°C for 10 hours, and then extruded at 330°C to form a round rod having a diameter of Φ25 mm, and thus the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use was obtained.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use had a tensile strength of 223 MPa, a yield strength of 188 MPa and an elongation of 24%. The corrosion rate of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use in artificial plasma was 0.32 mm/year. Biological test results showed that the material had no obvious cytotoxicity and good blood compatibility, which met the requirements for the biocompatibility of intravascular stent materials.
- This example provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use. The composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Nd, 0.4% of Zn, 0.4% of Ca, and balance of Mg.
- The magnesium alloy was prepared by the following steps:
- (1) In a vacuum melting furnace, pure magnesium having a purity of 99.99 wt% or more, pure Zn having a purity of 99.99 wt% or more, pure Ca having a purity of 99.99 wt% or more, and a Mg-30wt%Zr master alloy were successively melted, and the melt temperature during melting was controlled at 740 to 760°C. After the raw materials were completely melted, argon gas was introduced to conduct gas stirring in a vacuum environment with a stirring time of 40 min.
- (2) After the stirring was completed, a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) was introduced to the surface of the melt for protection, and at the same time, the temperature of the melt was raised to 760 to 780°C and kept for 30 min. After the high temperature insulation, the melting furnace was powered off, and the temperature of the melt was controlled at 700 to 720°C and the melt was allowed to stand for 90 min.
- (3) Subsequently, a copper crystallizer was used for the ingot casting on a semi-continuous casting machine. The magnesium alloy melt was introduced into a diverter plate placed in the core of the inner sleeve of the crystallizer, and was diverted by the diverter plate into the space formed by the metal inner sleeve and the dummy bar of the crystallizer. At the same time, the protective gas ring was opened to provide a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) to the alloy melt for protection. During the semi-continuous casting process, the temperature of the melt in the vacuum melting furnace was controlled at 700 to 720°C, the temperature of the melt in the crystallizer was 680 to 690°C, and the speed of ingot-drawing was 40 mm/min. High pressure water-cooling was applied at 400 mm close to the crystallizer, and air-cooling was applied at a lower region.
- (4) The Mg-Nd-Zn-Ca magnesium alloy semi-continuous ingot obtained from the casting had a size of Φ120×2400mm. The ingot had an appearance free of cracks and shrinkage, with a smooth and clean surface, fine and uniform structures, and no solute segregation.
- (5) The resultant Mg-Nd-Zn-Ca magnesium alloy ingot was cut to a certain length, subjected to solid solution treatment at 520°C for 10 hours, and then extruded at 330°C to form a round rod having a diameter of Φ25 mm, and thus the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use was obtained.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use had a tensile strength of 228 MPa, a yield strength of 196 MPa and an elongation of 21%. The corrosion rate of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use in artificial plasma was 0.36 mm/year. Biological test results showed that the material had no obvious cytotoxicity and good blood compatibility, which met the requirements for the biocompatibility of intravascular stent materials.
- This example provides a degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use. The composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Nd, 2.0% of Zn, 0.4% of Ca, 0.4% of Zr, and balance of Mg.
- The magnesium alloy was prepared by the following steps:
- (1) In a vacuum melting furnace, pure magnesium having a purity of 99.99 wt% or more, pure Zn having a purity of 99.99 wt% or more, pure Ca having a purity of 99.99 wt% or more, a Mg-30wt%Nd master alloy and a Mg-30wt%Zr master alloy were successively melted, and the melt temperature during melting was controlled at 740 to 760°C. After the raw materials were completely melted, argon gas was introduced to conduct gas stirring in a vacuum environment with a stirring time of 40 min.
- (2) After the stirring was completed, a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) was introduced to the surface of the melt for protection, and at the same time, the temperature of the melt was raised to 760 to 780°C and kept for 30 min. After the high temperature insulation, the melting furnace was powered off, and the temperature of the melt was controlled at 700 to 720°C and the melt was allowed to stand for 90 min.
- (3) Subsequently, a copper crystallizer was used for the ingot casting on a semi-continuous casting machine. The magnesium alloy melt was introduced into a diverter plate placed in the core of the inner sleeve of the crystallizer, and was diverted by the diverter plate into the space formed by the metal inner sleeve and the dummy bar of the crystallizer. At the same time, the protective gas ring was opened to provide a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) to the alloy melt for protection. During the semi-continuous casting process, the temperature of the melt in the vacuum melting furnace was controlled at 700 to 720°C, the temperature of the melt in the crystallizer was 680 to 690°C, and the speed of ingot-drawing was 40 mm/min. High pressure water-cooling was applied at 400 mm close to the crystallizer, and air-cooling was applied at a lower region.
- (4) The Mg-Nd-Zn-Ca-Zr magnesium alloy semi-continuous ingot obtained from the casting had a size of Φ120×2400mm. The ingot had an appearance free of cracks and shrinkage, with a smooth and clean surface, fine and uniform structures, and no solute segregation.
- (5) The resultant Mg-Nd-Zn-Ca-Zr magnesium alloy ingot was cut to a certain length, subjected to solid solution treatment at 520°C for 10 hours, and then extruded at 330°C to form a round rod having a diameter of Φ25 mm, and thus the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use was obtained.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use had a tensile strength of 256 MPa, a yield strength of 219 MPa and an elongation of 18%. The corrosion rate of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use in artificial plasma was 0.44 mm/year. Biological test results showed that the material had no obvious cytotoxicity and good blood compatibility, which met the requirements for the biocompatibility of intravascular stent materials.
- This comparative example provides a biomedical magnesium alloy. The composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Y, 0.4% of Zn, 0.4% of Zr, and balance of Mg.
- The magnesium alloy was prepared by the following steps:
- (1) In a vacuum melting furnace, pure magnesium having a purity of 99.99 wt% or more, pure Zn having a purity of 99.99 wt% or more, a Mg-30wt%Y master alloy and a Mg-30wt%Zr master alloy were successively melted, and the melt temperature during melting was controlled at 740 to 760°C. After the raw materials were completely melted, argon gas was introduced to conduct gas stirring in a vacuum environment with a stirring time of 40 min.
- (2) After the stirring was completed, a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) was introduced to the surface of the melt for protection, and at the same time, the temperature of the melt was raised to 760 to 780°C and kept for 30 min. After the high temperature insulation, the melting furnace was powered off, and the temperature of the melt was controlled at 700 to 720°C and the melt was allowed to stand for 90 min.
- (3) Subsequently, a copper crystallizer was used for the ingot casting on a semi-continuous casting machine. The magnesium alloy melt was introduced into a diverter plate placed in the core of the inner sleeve of the crystallizer, and was diverted by the diverter plate into the space formed by the metal inner sleeve and the dummy bar of the crystallizer. At the same time, the protective gas ring was opened to provide a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) to the alloy melt for protection. During the semi-continuous casting process, the temperature of the melt in the vacuum melting furnace was controlled at 700 to 720°C, the temperature of the melt in the crystallizer was 680 to 690°C, and the speed of ingot-drawing was 40 mm/min. High pressure water-cooling was applied at 400 mm close to the crystallizer, and air-cooling was applied at a lower region.
- (4) The Mg-Y-Zn-Zr magnesium alloy semi-continuous ingot obtained from the casting had a size of Φ120×2400mm. The ingot had an appearance free of cracks and shrinkage, with a smooth and clean surface, fine and uniform structures, and no solute segregation.
- (5) The resultant Mg-Y-Zn-Zr magnesium alloy ingot was cut to a certain length, subjected to solid solution treatment at 520°C for 10 hours, and then extruded at 330°C to form a round rod having a diameter of Φ25 mm, and thus the biomedical corrosion resistant high strength and toughness magnesium alloy was obtained.
- The biomedical magnesium alloy had a tensile strength of 216 MPa, a yield strength of 176 MPa and an elongation of 19%. The corrosion rate of the biomedical magnesium alloy in artificial plasma was 0.37 mm/year.
- This comparative example provides a biomedical magnesium alloy. The composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Y, 0.4% of Zn, 0.4% of Ca, and balance of Mg.
- The magnesium alloy was prepared by the following steps:
- (1) In a vacuum melting furnace, pure magnesium having a purity of 99.99 wt% or more, pure Zn having a purity of 99.99 wt% or more, pure Ca having a purity of 99.99 wt% or more, and a Mg-30wt%Y master alloy were successively melted, and the melt temperature during melting was controlled at 740 to 760°C. After the raw materials were completely melted, argon gas was introduced to conduct gas stirring in a vacuum environment with a stirring time of 40 min.
- (2) After the stirring was completed, a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) was introduced to the surface of the melt for protection, and at the same time, the temperature of the melt was raised to 760 to 780°C and kept for 30 min. After the high temperature insulation, the melting furnace was powered off, and the temperature of the melt was controlled at 700 to 720°C and the melt was allowed to stand for 90 min.
- (3) Subsequently, a copper crystallizer was used for the ingot casting on a semi-continuous casting machine. The magnesium alloy melt was introduced into a diverter plate placed in the core of the inner sleeve of the crystallizer, and was diverted by the diverter plate into the space formed by the metal inner sleeve and the dummy bar of the crystallizer. At the same time, the protective gas ring was opened to provide a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) to the alloy melt for protection. During the semi-continuous casting process, the temperature of the melt in the vacuum melting furnace was controlled at 700 to 720°C, the temperature of the melt in the crystallizer was 680 to 690°C, and the speed of ingot-drawing was 40 mm/min. High pressure water-cooling was applied at 400 mm close to the crystallizer, and air-cooling was applied at a lower region.
- (4) The Mg-Y-Zn-Ca magnesium alloy semi-continuous ingot obtained from the casting had a size of Φ120×2400mm. The ingot had an appearance free of cracks and shrinkage, with a smooth and clean surface, fine and uniform structures, and no solute segregation.
- (5) The resultant Mg-Y-Zn-Ca magnesium alloy ingot was cut to a certain length, subjected to solid solution treatment at 520°C for 10 hours, and then extruded at 330°C to form a round rod having a diameter of Φ25 mm, and thus the biomedical magnesium alloy was obtained.
- The biomedical magnesium alloy had a tensile strength of 213 MPa, a yield strength of 172 MPa and an elongation of 22%. The corrosion rate of the biomedical magnesium alloy in artificial plasma was 0.43 mm/year.
- This comparative example provides a biomedical magnesium alloy. The composition of the magnesium alloy comprises, with regard to a total weight of the magnesium alloy of 100%, 1.5% of Y, 2.0% of Zn, 0.4% of Ca, and balance of Mg.
- The magnesium alloy was prepared by the following steps:
- (1) In a vacuum melting furnace, pure magnesium having a purity of 99.99 wt% or more, pure Zn having a purity of 99.99 wt% or more, pure Ca having a purity of 99.99 wt% or more, a Mg-30wt%Y master alloy and a Mg-30wt%Zr master alloy were successively melted, and the melt temperature during melting was controlled at 740 to 760°C. After the raw materials were completely melted, argon gas was introduced to conduct gas stirring in a vacuum environment with a stirring time of 40 min.
- (2) After the stirring was completed, a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) was introduced to the surface of the melt for protection, and at the same time, the temperature of the melt was raised to 760 to 780°C and kept for 30 min. After the high temperature insulation, the melting furnace was powered off, and the temperature of the melt was controlled at 700 to 720°C and the melt was allowed to stand for 90 min.
- (3) Subsequently, a copper crystallizer was used for the ingot casting on a semi-continuous casting machine. The magnesium alloy melt was introduced into a diverter plate placed in the core of the inner sleeve of the crystallizer, and was diverted by the diverter plate into the space formed by the metal inner sleeve and the dummy bar of the crystallizer. At the same time, the protective gas ring was opened to provide a mixed gas of SF6 and CO2 (volume ratio of SF6:CO2 in this mixed gas being 1:100) to the alloy melt for protection. During the semi-continuous casting process, the temperature of the melt in the vacuum melting furnace was controlled at 700 to 720°C, the temperature of the melt in the crystallizer was 680 to 690°C, and the speed of ingot-drawing was 40 mm/min. High pressure water-cooling was applied at 400 mm close to the crystallizer, and air-cooling was applied at a lower region.
- (4) The Mg-Y-Zn-Ca-Zr magnesium alloy semi-continuous ingot obtained from the casting had a size of Φ120×2400mm. The ingot had an appearance free of cracks and shrinkage, with a smooth and clean surface, fine and uniform structures, and no solute segregation.
- (5) The resultant Mg-Y-Zn-Ca-Zr magnesium alloy ingot was cut to a certain length, subjected to solid solution treatment at 520°C for 10 hours, and then extruded at 330°C to form a round rod having a diameter of Φ25 mm, and thus the biomedical magnesium alloy was obtained.
- The biomedical magnesium alloy had a tensile strength of 236 MPa, a yield strength of 204 MPa and an elongation of 17%. The corrosion rate of the biomedical magnesium alloy in artificial plasma was 0.48 mm/year.
Table 1. Magnesium alloy composition and related properties Example No. Composition (wt%) Tensile strength (MPa) Yield Strength (MPa) Elongation (%) Corrosion rate (mm/year) Corrosion mode Example 1 Mg-1.5Nd-0.4Zn-0.4Ca-0.4Zr 246 207 34 0.26 Uniform corrosion Example 2 Mg-2.0Nd-0.6Zn-0.5Ca-0.6Zr 277 224 28 0.24 Uniform corrosion Example 3 Mg-2.5Nd-0.8Zn-0.6Ca-0.8Zr 289 232 25 0.22 Uniform corrosion Example 4 Mg-1.5Nd-0.4Zn-0.4Zr 223 188 24 0.32 - Example 5 Mg-1.5Nd-0.4Zn-0.4Ca 228 196 21 0.36 - Example 6 Mg-1.5Nd-2.0Zn-0.4Ca-0.4Zr 256 219 18 0.44 - Comparative Example 1 Mg-1.5Y-0.4Zn-0.4Zr 216 176 19 0.37 - Comparative Example 2 Mg-1.5Y-0.4Zn-0.4Ca 213 172 22 0.43 - Comparative Example 3 Mg-1.5Y-2.0Zn-0.4Ca-0.4Zr 236 204 17 0.48 - - As can be seen from Table 1, the magnesium alloy prepared by implementing the most preferred embodiments of the present invention has a tensile strength of 246 to 289 MPa, a yield strength of 207 to 232 MPa and an elongation rate of up to 25 to 34%, which meets the requirements for the mechanical properties of intravascular stent materials. Its corrosion rate in artificial plasma can reach 0.22 to 0.26 mm/year, which meets the requirement for the corrosion resistance of intravascular stent materials. In addition, the magnesium alloy has no obvious cytotoxicity and good blood compatibility, which meets the requirements for the biocompatibility of intravascular stent materials.
Claims (19)
- A degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use, wherein the composition of components of the magnesium alloy comprises 1.0 to 4.5% of Nd, 0.2 to 2.0% of Zn, 0 to 1.0% of Ca, 0 to 1.0% of Zr, and balance of Mg, with regard to a total weight of the magnesium alloy of 100%.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to claim 1, wherein the composition of components of the magnesium alloy comprises 1.5 to 3.5% of Nd, 0.1 to 1.0% of Zn, 0.1 to 1.0% of Ca, 0.2 to 1.0% of Zr, and balance of Mg, with regard to a total weight of the magnesium alloy of 100%.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to claim 1, wherein the composition of components of the magnesium alloy comprises 1.5 to 2.5% of Nd, 0.4 to 0.8% of Zn, 0.4 to 0.6% of Ca, 0.4 to 0.8% of Zr, and balance of Mg, with regard to a total weight of the magnesium alloy of 100%.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to any of claims 1 to 3, wherein the total amount of inclusion elements other than Mg, Nd, Zn, Ca, and Zr contained in the magnesium alloy is 0.05% or less, with regard to a total weight of the magnesium alloy of 100%.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to claim 1, which is prepared by at least the step of:preparing a magnesium alloy ingot by means of vacuum semi-continuous casting and according to the components and weight percentage in the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use, wherein the raw materials used comprise at least: pure Zn, a Mg-Nd master alloy, and pure magnesium.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to claim 5, wherein the raw materials used further comprise pure Ca and/or a Mg-Zr master alloy.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to claim 5, wherein the pure Zn used has a purity of 99.99 wt% or more, the Mg-Nd master alloy used is a Mg-30wt%Nd master alloy, and the pure magnesium used has a purity of 99.99 wt% or more.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to claim 6, wherein the pure Ca used has a purity of 99.99 wt% or more, and the Mg-Zr master alloy used is a Mg-30wt%Zr master alloy.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to claim 5, wherein the resultant magnesium alloy ingot has a size of Φ110 to 150 mm in diameter and 2200 to 2600 mm in length.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to claim 5, wherein the preparation of the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use further comprises: cutting the resultant magnesium alloy ingot to a certain length, and subjecting it to solid solution treatment before extruding, so as to obtain the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use.
- The degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to claim 10, wherein the temperature for the solid solution treatment is 480 to 540°C, the duration of the solid solution treatment is 8 to 12 hours, the extrusion is performed at an extruding ratio of 5 to 30 in an environment at 280 to 420°C, and the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use is obtained after the extrusion as a round rod with a diameter of Φ20 to 40 mm.
- A preparation method for the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use according to any one of claims 1-11, comprising at least the step of: preparing a magnesium alloy ingot by means of vacuum semi-continuous casting and according to the components and weight percentage in the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use, wherein the raw materials used comprise at least: pure Zn, a Mg-Nd master alloy, and pure magnesium.
- The preparation method according to claim 12, wherein the raw materials used further comprise pure Ca and/or a Mg-Zr master alloy.
- The preparation method according to claim 12, wherein the pure Zn used has a purity of 99.99 wt% or more, the Mg-Nd master alloy used is a Mg-30wt%Nd master alloy, and the pure magnesium used has a purity of 99.99 wt% or more.
- The preparation method according to claim 13, wherein the pure Ca used has a purity of 99.99 wt% or more, and the Mg-Zr master alloy used is a Mg-30wt%Zr master alloy.
- The preparation method according to claim 12, wherein the vacuum semi-continuous casting comprises the following steps:(1) the raw materials are melted in a vacuum melting furnace with a melt temperature controlled at 740 to 760°C during melting, and after the raw materials are completely melted, an inert gas is introduced for stirring by gas in a vacuum environment with a stirring time of 30 to 45 min;(2) after the stirring is completed, a mixed gas of SF6 and CO2 is introduced to the surface of the melt for protection while the temperature of the melt is raised to 760 to 780°C and kept for 30 to 40 min, and then the temperature of the melt is lowered to 700 to 720°C and the melt is allowed to stand for 90 to 120 min;(3) casting is then carried out on a semi-continuous casting machine; during the semi-continuous casting process, a gas mixture of SF6 and CO2 is used for protection, the temperature of the melt in the vacuum melting furnace is controlled at 700 to 720°C, with the temperature of the melt in a crystallizer at 680 to 690°C and a speed of ingot-drawing of 30 to 50 mm/min, and high pressure water-cooling is applied at 300 to 500 mm close to the crystallizer while air-cooling is applied at a lower region, thereby obtaining the magnesium alloy ingot.
- The preparation method according to claim 12, wherein the resultant magnesium alloy ingot has a size of Φ110 to 150 mm in diameter and 2200 to 2600 mm in length.
- The preparation method according to claim 12, further comprising the following steps: cutting the obtained magnesium alloy ingot to a certain length, and subjecting it to solid solution treatment before extruding, so as to obtain the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use.
- The preparation method according to claim 18, wherein the temperature for the solid solution treatment is 480 to 540°C, the duration of the solid solution treatment is 8 to 12 hours, the extrusion is performed at an extruding ratio of 5 to 30 in an environment at 280 to 420°C, and the degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use is obtained after the extrusion as a round rod with a diameter of Φ20 to 40 mm.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2016/087575 WO2018000219A1 (en) | 2016-06-29 | 2016-06-29 | Degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use and preparation method therefor |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3403676A1 true EP3403676A1 (en) | 2018-11-21 |
EP3403676A4 EP3403676A4 (en) | 2019-02-20 |
EP3403676B1 EP3403676B1 (en) | 2022-03-23 |
Family
ID=60785035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16906621.4A Active EP3403676B1 (en) | 2016-06-29 | 2016-06-29 | Degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use and preparation method therefor |
Country Status (4)
Country | Link |
---|---|
US (1) | US11040126B2 (en) |
EP (1) | EP3403676B1 (en) |
ES (1) | ES2912456T3 (en) |
WO (1) | WO2018000219A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110144503A (en) * | 2019-05-07 | 2019-08-20 | 珠海中科先进技术研究院有限公司 | A kind of high-strength anticorrosion magnesium alloy and preparation method thereof |
CN114231811A (en) * | 2021-12-17 | 2022-03-25 | 中国兵器科学研究院宁波分院 | Mg-Nd-Zr-Sr-Sc-Sm biodegradable magnesium alloy and preparation method thereof |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111826564A (en) * | 2019-04-15 | 2020-10-27 | 中国科学院金属研究所 | Absorbable magnesium alloy cosmetic line and preparation method thereof |
CN111228577A (en) * | 2020-01-15 | 2020-06-05 | 太原科技大学 | Medical magnesium alloy capable of being degraded in short term and preparation method thereof |
CN112472868B (en) * | 2020-11-18 | 2024-02-23 | 郑州大学 | Degradable Mg-Nd-Zn-Sc biomedical magnesium alloy and preparation method thereof |
CN112742892A (en) * | 2020-12-18 | 2021-05-04 | 上海康德莱医疗器械股份有限公司 | Medical magnesium alloy pipe and preparation method thereof |
CN114351020B (en) * | 2021-12-30 | 2022-12-13 | 台山市中镁科技有限公司 | Magnesium alloy casting and preparation method and application thereof |
CN115109975A (en) * | 2022-05-27 | 2022-09-27 | 季华实验室 | Magnesium alloy containing precipitation strengthening phase of nano core-shell structure and preparation method thereof |
CN115233060B (en) * | 2022-08-12 | 2023-02-03 | 吉林大学 | High-strength weak-texture Mg-Zn-Y-Ca-Zr magnesium alloy with low alloy content and preparation method thereof |
CN115369341B (en) * | 2022-08-29 | 2023-08-29 | 广东腐蚀科学与技术创新研究院 | Composite biological magnesium alloy material and preparation method thereof |
CN117144218A (en) * | 2023-09-15 | 2023-12-01 | 株洲宜安精密制造有限公司 | High-strength magnesium alloy and preparation method and application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0710355A2 (en) | 2006-04-28 | 2011-08-09 | Biomagnesium Systems Ltd | biodegradable magnesium alloys and uses thereof |
CN101062427A (en) | 2006-04-29 | 2007-10-31 | 中国科学院金属研究所 | Medical corrosion-resisting type magnesium alloy |
CN100998893B (en) * | 2006-12-26 | 2010-05-12 | 重庆大学 | Biodegradable rare earth magnesium alloy material |
CN101288776A (en) | 2007-04-18 | 2008-10-22 | 中国科学院金属研究所 | Medical high-strength anticorrosion magnesium alloy |
CN101629260A (en) | 2008-07-18 | 2010-01-20 | 中国科学院金属研究所 | Medical absorbable Mg-Zn-Mn-Ca magnesium alloy |
JP5540780B2 (en) * | 2009-05-29 | 2014-07-02 | 住友電気工業株式会社 | Magnesium alloy wire, bolt, nut and washer |
CN101643872B (en) | 2009-09-01 | 2011-11-02 | 吉林大学 | High-strength high-plasticity magnesium alloy and preparation method thereof |
CN101837145B (en) | 2010-06-22 | 2013-01-09 | 上海交通大学 | High-toughness corrosion-resistant magnesium alloy implanted material capable of being degraded in organism |
CN101985714B (en) | 2010-12-07 | 2012-09-26 | 吉林大学 | High-plasticity magnesium alloy and preparation method thereof |
DE102012108089A1 (en) | 2012-08-31 | 2014-05-15 | Gottfried Wilhelm Leibniz Universität Hannover | Magnesium alloy used for formation of work samples used as medical device e.g. implant and suture, comprises magnesium and zinc, and rare-earth metal in specified weight ratio |
CN103184379B (en) | 2013-03-29 | 2015-10-07 | 江苏康欣医疗设备有限公司 | Biodegradable Mg-Gd-Zn-Ag-Zr series magnesium alloy and preparation method thereof |
CN103774017B (en) * | 2014-01-18 | 2016-01-13 | 中南大学 | The semicontinuous casting technique of strength heatproof magnesium alloy ingot casting in major diameter |
CN104164602B (en) * | 2014-08-06 | 2016-03-09 | 哈尔滨工程大学 | A kind of preparation method of medical magnesium alloy of can evenly degrading |
-
2016
- 2016-06-29 US US16/312,261 patent/US11040126B2/en active Active
- 2016-06-29 WO PCT/CN2016/087575 patent/WO2018000219A1/en active Application Filing
- 2016-06-29 EP EP16906621.4A patent/EP3403676B1/en active Active
- 2016-06-29 ES ES16906621T patent/ES2912456T3/en active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110144503A (en) * | 2019-05-07 | 2019-08-20 | 珠海中科先进技术研究院有限公司 | A kind of high-strength anticorrosion magnesium alloy and preparation method thereof |
CN114231811A (en) * | 2021-12-17 | 2022-03-25 | 中国兵器科学研究院宁波分院 | Mg-Nd-Zr-Sr-Sc-Sm biodegradable magnesium alloy and preparation method thereof |
CN114231811B (en) * | 2021-12-17 | 2022-09-09 | 中国兵器科学研究院宁波分院 | Mg-Nd-Zr-Sr-Sc-Sm biodegradable magnesium alloy and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
EP3403676A4 (en) | 2019-02-20 |
WO2018000219A1 (en) | 2018-01-04 |
ES2912456T3 (en) | 2022-05-26 |
EP3403676B1 (en) | 2022-03-23 |
US20190201590A1 (en) | 2019-07-04 |
US11040126B2 (en) | 2021-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3403676B1 (en) | Degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use and preparation method therefor | |
JP6431957B2 (en) | Biodegradable metal alloy | |
US20210137709A1 (en) | Bioerodible magnesium alloy microstructures for endoprostheses | |
CN107557632B (en) | Degradable biomedical Mg-Zn-Zr-Nd alloy material and preparation method thereof | |
US10604827B2 (en) | Biodegradable metal alloys | |
CN110144503B (en) | High-strength-toughness corrosion-resistant magnesium alloy and preparation method thereof | |
EP3038666B1 (en) | Bioerodible composites for endoprostheses | |
CN107541631B (en) | A kind of biological medical degradable corrosion-proof and high-strength tough magnesium alloy and preparation method thereof | |
WO2011160534A1 (en) | Magnesium alloy used for degradable stent material in vivo and preparation method thereof | |
EP2213314B1 (en) | Implant with a base body of a biocorrodible magnesium alloy | |
EP3062832B1 (en) | Bioerodible magnesium alloy microstructures for endoprostheses | |
CN103184379B (en) | Biodegradable Mg-Gd-Zn-Ag-Zr series magnesium alloy and preparation method thereof | |
WO2017084363A1 (en) | Medical degradable zn-cu-x alloy material and preparation method thereof | |
CN108754232B (en) | High-strength high-plasticity biodegradable Zn-Mn-Li series zinc alloy and application thereof | |
JP2015524512A (en) | Magnesium alloy, method for producing the same and use thereof | |
US10589005B2 (en) | Bioerodible magnesium alloy microstructures for endoprostheses | |
CN110117743B (en) | Corrosion-resistant high-strength toughness magnesium alloy pipe and preparation process thereof | |
CN109602960B (en) | Preparation method of medical zinc alloy bar with superplasticity | |
CN111187943A (en) | Biomedical Zn-Cu-Mg alloy and preparation method thereof | |
CN102258806A (en) | Degradable magnesium-base biomedical material for implantation in orthopaedics, and preparation method thereof | |
CN107198796B (en) | Biomedical Zn-Mn-Cu zinc alloy and preparation method thereof | |
CN112494725A (en) | Biodegradable composite material and preparation method and application thereof | |
EP4272774A1 (en) | Biodegradable magnesium alloy free of rare earth element, and preparation method and use thereof | |
CN112899527B (en) | Degradable zinc alloy bar and preparation method thereof | |
CN115927940B (en) | Mg-Y-Sr-Pr-Zr-Ca biodegradable magnesium alloy and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180814 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190118 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61L 31/02 20060101AFI20190114BHEP Ipc: A61L 31/14 20060101ALI20190114BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200603 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C22C 23/00 20060101ALI20210901BHEP Ipc: A61L 31/14 20060101ALI20210901BHEP Ipc: A61L 31/02 20060101AFI20210901BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20211015 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016070397 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1477007 Country of ref document: AT Kind code of ref document: T Effective date: 20220415 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2912456 Country of ref document: ES Kind code of ref document: T3 Effective date: 20220526 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20220323 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220623 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220623 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1477007 Country of ref document: AT Kind code of ref document: T Effective date: 20220323 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220624 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220725 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220723 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016070397 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20220630 |
|
26N | No opposition filed |
Effective date: 20230102 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220629 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220629 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230612 Year of fee payment: 8 Ref country code: FR Payment date: 20230620 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230601 Year of fee payment: 8 Ref country code: ES Payment date: 20230711 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20160629 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220323 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240529 Year of fee payment: 9 |